Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population.
Fancelli S, Caliman E, Mazzoni F, Paglialunga L, Gatta Michelet MR, Lavacchi D, Berardi R, Mentrasti G, Metro G, Birocchi I, Delmonte A, Priano I, Comin CE, Castiglione F, Bartoli C, Voltolini L, Pillozzi S, Antonuzzo L. Fancelli S, et al. Among authors: castiglione f. Front Oncol. 2022 Nov 14;12:968064. doi: 10.3389/fonc.2022.968064. eCollection 2022. Front Oncol. 2022. PMID: 36452502 Free PMC article.
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer.
Lavacchi D, Fancelli S, Roviello G, Castiglione F, Caliman E, Rossi G, Venturini J, Pellegrini E, Brugia M, Vannini A, Bartoli C, Cianchi F, Pillozzi S, Antonuzzo L. Lavacchi D, et al. Among authors: castiglione f. Front Oncol. 2022 Nov 29;12:1055019. doi: 10.3389/fonc.2022.1055019. eCollection 2022. Front Oncol. 2022. PMID: 36523988 Free PMC article.
Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian Cancer.
Pardella E, Pranzini E, Nesi I, Parri M, Spatafora P, Torre E, Muccilli A, Castiglione F, Fambrini M, Sorbi F, Cirri P, Caselli A, Puhr M, Klocker H, Serni S, Raugei G, Magherini F, Taddei ML. Pardella E, et al. Among authors: castiglione f. Cells. 2022 Dec 13;11(24):4026. doi: 10.3390/cells11244026. Cells. 2022. PMID: 36552790 Free PMC article.
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size.
Sparano C, Rotondi M, Verdiani V, Brunori P, Castiglione F, Bartoli C, Perigli G, Badii B, Vezzosi V, Simontacchi G, Livi L, Antonuzzo L, Maggi M, Petrone L. Sparano C, et al. Among authors: castiglione f. J Endocr Soc. 2022 Oct 13;6(12):bvac157. doi: 10.1210/jendso/bvac157. eCollection 2022 Oct 26. J Endocr Soc. 2022. PMID: 36397778 Free PMC article.
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
Mandalà M, Palmieri G, Ludovini V, Baglivo S, Marasciulo F, Castiglione F, Gili A, Osella Abate S, Rubatto M, Senetta R, Avallone G, Ribero S, Romano L, Pimpinelli N, de Giorgi V, Roila F, Pisano M, Casula M, Manca A, Sini MC, Massi D, Quaglino P; Italian Melanoma Intergroup (IMI). Mandalà M, et al. Among authors: castiglione f. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):1991-1998. doi: 10.1111/jdv.19281. Epub 2023 Jun 27. J Eur Acad Dermatol Venereol. 2023. PMID: 37335879
611 results